Respondents see the glucagon-like peptide 1 (GLP-1) drugs as a major advance. They also have concerns about whether insurers ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Two-thirds (66%) of the respondents to the MHE survey said they expect Prescription Drug User Fee Act (PDUFA) dates to be ...

The FDA has granted Mesoblast’s stem cell therapy, Ryoncil (remestemcel-L), seven years of orphan drug exclusivity for the ...

Eric Tichy, Pharm.D., M.B.A., vice chair of pharmacy formulary at the Mayo Clinic Health System, explains potential ...

Bayer’s Jivi is a factor VIII replacement therapy that has been engineered with a compound that allows for less frequent dosing. It is now indicated for patients 7 years of age and older.

Men and people ages 45 and older face additional risk of serious kidney conditions six to 12 months after their viral illness ...

A personalized gene editing therapy was successfully used to treat an infant with CPS1 deficiency, a disease that causes ...

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the ...

In a news release, Guthrie, the comitteee chair, heralded the committee’s plan, (which also cuts in green energy and other ...

FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

Results of a real-world study that included people with hemophilia from 33 countries show that people with hemophilia B, ...